(2S)-2-amino-2-[1-[(2-amino-6-oxo-1H-purin-9-yl)methoxy]ethyl]-3-methylbutanoic acid

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 咪唑并嘧啶类
• 英文名称: (2S)-2-amino-2-[1-[(2-amino-6-oxo-1H-purin-9-yl)methoxy]ethyl]-3-methylbutanoic acid
• 化学式: C₁₃H₂₀N₆O₄
• 分子量: 324.34
• InChiKey: OHBMNVKWVFNEHN-GRSHUZJTSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -2.4
• 重原子数：
  23
• 可旋转键数：
  6
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.54
• 拓扑面积：
  158
• 氢给体数：
  4
• 氢受体数：
  6

文献信息

• SUBSTITUTED METHYLFORMYL REAGENTS AND METHOD OF USING SAME TO MODIFY PHYSICOCHEMICAL AND/OR PHARMACOKINETIC PROPERTIES OF COMPOUNDS
  申请人：Dugar Sundeep

  公开号：US20140121367A1

  公开（公告）日：2014-05-01

  The present invention relates to the synthesis and application of novel chiral/achiral substituted methyl formyl reagents to modify pharmaceutical agents and/or biologically active substances to modify the physicochemical, biological and/or pharmacokinetic properties of the resulting compounds from the unmodified original agent.

  本发明涉及合成和应用新型手性/无手性取代甲基甲酰试剂来修饰药物和/或生物活性物质，以改变未经修饰的原始试剂的物理化学、生物学和/或药代动力学性质，从而得到改性后的化合物。
• COMBINED SYSTEMIC AND TOPICAL TREATMENT OF DISORDERED TISSUES
  申请人：Quadex Pharmaceuticals, LLC

  公开号：EP2968228A1

  公开（公告）日：2016-01-20
• TOPICAL APPLICATION FOR AN ANTI-HSV ANTIBODY
  申请人：Heidelberg ImmunoTherapeutics GmbH

  公开号：EP3160997A1

  公开（公告）日：2017-05-03
• COMBINED SYSTEMIC AND TOPICAL TREATMENT OF DISORDERED AND/OR PRODROMAL STAGE TISSUE
  申请人：QUADEX PHARMACEUTICALS, LLC

  公开号：US20150374704A1

  公开（公告）日：2015-12-31

  Compositions and methods for treating disordered and/or prodromal stage tissue infected with by a virus in a mammal by co-administering a systemic anti-virus drug and topically administered anti-infective composition. The systemic anti-virus drug is internally administered and disrupts or inhibits virus replication systemically within the mammal. Examples include nucleoside analogues, nucleoside analogue precursors, and nucleotide analogues. The topically administered anti-infective composition includes at least one anti-infective agent, such as an organohalide (e.g., benzalkonium chloride), and is formulated to penetrate below the skin surface and allow the anti-infective agent to kill viruses at a treatment site. The topical anti-infective composition enhances efficacy of the systemic anti-virus drug and reduces the time and/or number of dosages otherwise required for the systemic anti-virus drug to treat the viral infection. The topical anti-infective composition can be more beneficial than the systemic anti-virus drug in killing viruses and can reduce or eliminate post-herpetic neuralgia.
• US9359376B2
  申请人：——

  公开号：US9359376B2

  公开（公告）日：2016-06-07